GHK-Cu Injectable

Copper-binding tripeptide involved in tissue remodeling pathways.

Overview

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide found in human plasma that declines with age. Research — primarily in vitro and animal studies — suggests involvement in tissue remodeling, wound healing, and gene expression regulation. Human clinical data is more limited. This is a compounded peptide therapy, not an FDA-approved medication.

Mechanism

GHK-Cu has been studied in the context of collagen synthesis, anti-inflammatory signaling, and tissue repair. It is thought to act by modulating gene expression. The breadth of genes potentially influenced in vitro does not necessarily predict equivalent systemic effects in humans at clinical doses.

Clinical Considerations

• Injectable form provides systemic delivery.
• Injection site reactions are possible.
• No specific anti-aging or cosmetic outcome is guaranteed. Results are individual.

Potential Side Effects

• Injection site redness or mild discomfort — typical for SubQ injections.
• Metallic taste reported by some users due to the copper component.
• No serious adverse events prominently reported in available literature at standard doses.

All prescriptions require a telehealth consultation with a licensed provider. A prescription is not guaranteed. Individual results vary. Not FDA-approved unless noted otherwise.